Observation of the Heavy Baryons Sigma b and Sigma b*

We report an observation of new bottom baryons produced in pp collisions at the Tevatron. Using 1.1 fb(-1) of data collected by the CDF II detector, we observe four Lambda b 0 pi+/- resonances in the fully reconstructed decay mode Lambda b 0-->Lambda c + pi-, where Lambda c+-->pK* pi+. We interpret these states as the Sigma b(*)+/- baryons and measure the following masses: m Sigma b+=5807.8 -2.2 +2.0(stat.)+/-1.7(syst.) MeV/c2, m Sigma b- =5815.2+/-1.0(stat.)+/-1.7(syst.) MeV/c2, and m(Sigma b*)-m(Sigma b)=21.2-1.9 +2.0(stat.)-0.3+0.4(syst.) MeV/c2.

Search for chargino-neutralino production in pp collisions at sq rt[s] = 1.96 TeV

We present a search for associated production of the chargino and neutralino supersymmetric particles using up to 1.1 fb{-1} of integrated luminosity collected by the CDF II experiment at the Tevatron pp collider at sq rt[s]=1.96 TeV. We analyze events with a large transverse momentum imbalance and either three charged leptons or two charged leptons of the same electric charge. The numbers of observed events are consistent with standard model expectations. Upper limits on the production cross section are derived in different theoretical models.

Precise measurement of the top-quark mass in the lepton+jets topology at CDF II

We present a measurement of the mass of the top quark from proton-antiproton collisions recorded at the CDF experiment in Run II of the Fermilab Tevatron. We analyze events from the single lepton plus jets final state (tt-->W(+)bW(-)b-->lnubqq'b). The top-quark mass is extracted using a direct calculation of the probability density that each event corresponds to the tt final state. The probability is a function of both the mass of the top quark and the energy scale of the calorimeter jets, which is constrained in situ by the hadronic W boson mass. Using 167 events observed in 955 pb(-1) of integrated luminosity, we achieve the single most precise measurement of the top-quark mass, 170.8+/-2.2(stat.)+/-1.4(syst.) GeV/c(2).

Search for new physics in high-mass electron-positron events in pp[over] collisions at square root s = 1.96 TeV

We report the results of a search for a narrow resonance in electron-positron events in the invariant mass range of 150-950 GeV/c(2) using 1.3 fb(-1) of pp[over] collision data at square root s = 1.96 TeV collected by the CDF II detector at Fermilab. No significant evidence of such a resonance is observed and we interpret the results to exclude the standard-model-like Z' with a mass below 923 GeV/c(2) and the Randall-Sundrum graviton with a mass below 807 GeV/c(2) for k/M[over](pl) = 0.1, both at the 95% confidence level. Combining with diphoton data excludes the Randall-Sundrum graviton for masses below 889 GeV/c(2) for k/M[over](pl) = 0.1.

Search for high-mass diphoton states and limits on Randall-Sundrum gravitons at CDF

We have performed a search for new particles which decay to two photons using 1.2 fb(-1) of integrated luminosity from pp[over] collisions at square root s = 1.96 TeV collected using the CDF II detector at the Fermilab Tevatron. We find the diphoton mass spectrum to be in agreement with the standard model expectation, and set limits on the cross section times branching ratio for the Randall-Sundrum graviton, as a function of diphoton mass. We subsequently derive lower limits for the graviton mass of 230 GeV/c(2) and 850 GeV/c(2), at the 95% confidence level, for coupling parameters (k/M[over](Pl)) of 0.01 and 0.1, respectively.

First measurement of the W-boson mass in run II of the Tevatron

We present a measurement of the W-boson mass using 200 pb{-1} of data collected in pp[over ] collisions at sqrt[s]=1.96 TeV by the CDF II detector at run II of the Fermilab Tevatron. With a sample of 63 964 W-->enu candidates and 51 128 W-->munu candidates, we measure M_{W}=80 413+/-34{stat}+/-34{syst}=80,413+/-48 MeV/c;{2}. This is the most precise single measurement of the W-boson mass to date.

Polarizations of J/psi and psi(2S) mesons produced in pp collisions at square root s = 1.96 TeV

We have measured the polarizations of J/psi and psi(2S) mesons as functions of their transverse momentum p(T) when they are produced promptly in the rapidity range |y| < 0.6 with p(T) > or =5 GeV/c. The analysis is performed using a data sample with an integrated luminosity of about 800 pb(-1) collected by the CDF II detector. For both vector mesons, we find that the polarizations become increasingly longitudinal as p(T) increases from 5 to 30 GeV/c. These results are compared to the predictions of nonrelativistic quantum chromodynamics and other contemporary models. The effective polarizations of J/psi and psi(2S) mesons from B-hadron decays are also reported.

Search for heavy long-lived particles that decay to photons at CDF II

We present the first search for heavy, long-lived particles that decay to photons at a hadron collider. We use a sample of gamma + jet + missing transverse energy events in pp[over] collisions at square root[s] = 1.96 TeV taken with the CDF II detector. Candidate events are selected based on the arrival time of the photon at the detector. Using an integrated luminosity of 570 pb(-1) of collision data, we observe 2 events, consistent with the background estimate of 1.3+/-0.7 events. While our search strategy does not rely on model-specific dynamics, we set cross section limits in a supersymmetric model with [Formula: see text] and place the world-best 95% C.L. lower limit on the [Formula: see text] mass of 101 GeV/c(2) at [Formula: see text].

Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer

Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapatinib from preclinical studies to the pivotal Phase III trial and ongoing clinical studies. Areas of interest include the advantages of small molecule TKIs versus antibodies in targeting HER receptors and the efficacy of lapatinib in the treatment of cerebral metastases. The surprisingly high response rate in inflammatory breast cancer raises the possibility of other novel predictive biomarkers. The potential for combination and sequencing with other biological and cytotoxic agents is both exciting and challenging.

Mathematical modelling of toxicity-related trade-offs in metronomic chemotherapy

For better quality of life (QoL) for the cancer patients, metronomic chemotherapy (MCT) would be the rational option instead of conventional chemotherapy. However, in view of the recent arguments regarding the accumulation of toxicity in MCT, it is worthwhile to examine the role of pathophysiological constraints in retarding the curative potential of MCT. Drug application is stopped upon attaining a certain high level of toxicity and subsequent resumption is possible once the toxicity drops below a certain low level. Large delays in subsequent drug administration can thus effectively handle toxicity and it may retard the therapeutic potential due to excessive tumour growth in the absence of drug. Small delays, on the other hand, may result in inoperable pathophysiological states resulting in poor QoL. It is argued that only the intervention of domain knowledge of an expert oncologist with respect to drug administration decision can in fact clinch the trade-off issues arising out of the situation in favour of a sustainable QoL. A mathematical model that may act as a general guideline to tackle the trade-off issues in cancer treatment is provided. Rigorous simulation exercises are required to establish the concept of MCT in the backdrop of conventional cancer treatment practices.

Application of Data Mining Techniques for Proper Design of Knowledge Repository

This paper reports a basic assessment of the usage of a knowledge repository called "XYZ Knowledge Repository", maintained by a company PQR for its client XYZ. Subsequently, a data mining method for finding sequential patterns in the web usage of the users was used. This captures the level of association between the web pages through two parameters, support and confidence. Depending upon the values of these two parameters, concepts of strong association, weak association and no association are realised. In case of strong association we recommended the pages be grouped together; while in the case of weak association, a link may be provided.

Observation and mass measurement of the baryon Xib-

We report the observation and measurement of the mass of the bottom, strange baryon Xi(b)- through the decay chain Xi(b)- -->J/psiXi-, where J/psi-->mu+mu-, Xi- -->Lambdapi-, and Lambda-->ppi-. A signal is observed whose probability of arising from a background fluctuation is 6.6 x 10(-15), or 7.7 Gaussian standard deviations. The Xi(b)- mass is measured to be 5792.9+/-2.5(stat) +/- 1.7(syst) MeV/c2.

First measurement of the ratio of central-electron to forward-electron W partial cross sections in pp[over] collisions at (square root)s =1.96 TeV

We present a measurement of sigma(pp[over] --> W) x B(W --> e nu) at (square root)s = 1.96 TeV, using electrons identified in the forward region (1.2 < |eta| < 2.8) of the CDF II detector, in 223 pb(-1) of data. We measure sigma x B = 2796 +/- 13(stat)(-90)(+95)(syst) +/- 162(lum) pb. Combining this result with a previous CDF measurement obtained using electrons in the central region (|eta| approximately < 1), we present the first measurement of the ratio of central-electron to forward-electron W partial cross sections R(exp) = 0.925 +/- 0.006(stat) +/- 0.032(syst), consistent with theoretical predictions using Coordinated Theoretical-Experimental Project on QCD (CTEQ) and Martin-Roberts-Stirling-Thorne (MRST) parton distribution functions.

Quantitative measurement of HER2 expression and HER2 homo-dimerization in formalin-fixed paraffin-embedded (FFPE) breast cancer tissues using a novel proximity-based assay

21023

Background: The best method to assess HER2 status remains controversial. Here we describe a novel assay that provides reliable quantitation of total HER2 (H2T) and HER2 homodimer (H22D) in FFPE tissues. The assay was cross-validated with conventional HER2 tests - immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Characteristics of the new assay and its potential application as predictive test were explored. Methods: Electrophoretic Tag (eTag) is a proprietary proximity-based technology that measures gene and protein expression. We have developed a novel application of the technology to quantify H2T and H22D in FFPE tissues. The validity of the assay was evaluated by analyzing its performance in cell lines and FFPE breast cancers. IHC (clone CB-11, Ventana) was performed in 174 breast cancers, scored according to standard IHC criteria and Histoscore (H-score), and HER2 gene amplification was evaluated by FISH (PathVysion, Vysis) in 19 breast cancers. eTag assays were performed on the same specimens and the results were compared with those of IHC and FISH. Results: H2T and H22D were proportional to the known expression levels in cell lines. H2T demonstrated a continuous measurement over a wide dynamic range (>2 logs), in contrast with conventional IHC (0, 1+, 2+, 3+). The correlation between H2T and IHC categories was significant (correlation=0.84, p<0.0001 by the Jonckheere-Terpstra test for trend), but overlap of H2T values in adjacent IHC categories was observed. H-score showed good correlation within the lower range of H2T, but plateaued at higher range of H2T. HER2 gene amplification (HER2/CEP17 ratio and gene copy #) by FISH was generally correlated with IHC categories and H2T values. There was a good correlation between H22D and H2T (r2= 0.7, P < 0.001). Conclusions: eTag reliably measures H2T and H22D in FFPE tissues. The continuous measure of H2T over a wide dynamic range and the novel H22D measure provide data superior to conventional HER2 tests by IHC and FISH, but clinical utility of the eTag assay remains to be investigated. eTag has potential as a predictive test for targeted HER2 therapy in breast cancer.

No significant financial relationships to disclose.

A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines

BACKGROUND AND PURPOSE

PMX464 is a novel benzothiazole substituted cyclohexadienone reportedly targeting the thioredoxin (Trx1)/thioredoxin reductase (TrxR1) system. We have previously shown that PMX464 has enhanced hypoxic anti-proliferative effects in colorectal tumour cells, with some non-tumour cells (quiescent endothelium and fibroblasts) being relatively resistant. The current study aimed to validate the Trx1 system as a molecular target of PMX464 in tumour cells and to investigate the differential sensitivities of normal cells at the molecular level.

EXPERIMENTAL APPROACH

Proliferation, clonogenic survival, protein expression and function, cell cycle and apoptosis assays were conducted using colorectal tumour (HT29), endothelial (HUVEC) and fibroblast (MRCV) cells treated with PMX464 under normoxic and hypoxic (1% O(2)) conditions.

KEY RESULTS

Protein and enzyme assays showed that PMX464, in HT29, inhibited Trx1 function without altering expression and that inhibition correlated with decreased proliferation and survival, and was more marked under hypoxia. In contrast, although hypoxic HUVEC were sensitive, in terms of proliferation and survival, inhibition of Trx1 function was not observed. Quiescent HUVEC and MRCVs (that have undetectable Trx1 protein) were relatively resistant. The effect on HT29 cells was essentially due to cell cycle inhibition, as apoptosis was modest. Anti-proliferative effects were lost after a lag period, suggesting a reversible phenomenon.

CONCLUSIONS AND IMPLICATIONS

The Trx1 system is an important target in tumour cells and can be inhibited by PMX464. Quiescent HUVEC and fibroblasts are relatively resistant conferring a therapeutic benefit when targeting Trx1.

Measurement of sigma chi c2 B(chi c2-->J/psi gamma)/sigma chi c1 B(chi c1 -->J/psi gamma) in pp collisions at square root s=1.96 TeV

We measure the ratio of cross section times branching fraction, Rp=sigma chi c2 B(chi c2-->J/psi gamma)/sigma chi c1 B(chi c1-->J/psi gamma), in 1.1 fb(-1) of pp collisions at square root s=1.96 TeV. This measurement covers the kinematic range pT(J/psi)>4.0 GeV/c, |eta(J/psi)<1.0, and pT(gamma)>1.0 GeV/c. For events due to prompt processes, we find Rp=0.395+/-0.016(stat)+/-0.015(syst). This result represents a significant improvement in precision over previous measurements of prompt chi c1,2 hadro production.

Inclusive search for new physics with like-sign dilepton events in pp collisions at square root of s =1.96 TeV

We describe a search for anomalous production of events with two leptons (e or mu) of the same electric charge in pp[over ] collisions at a center-of-mass energy of 1.96 TeV. Many extensions to the standard model predict the production of two leptons of the same electric charge. This search has a significant increase in sensitivity compared to earlier searches. Using a data sample corresponding to 1 fb(-1) of integrated luminosity recorded by the CDF II detector, we observe no significant excess in an inclusive selection (expect 33.2+/-4.7 events, observe 44) or in a supersymmetry-optimized selection (expect 7.8+/-1.1 events, observe 13.).

Observation of WZ production

We report the first observation of the associated production of a W boson and a Z boson. This result is based on 1.1 fb;-1 of integrated luminosity from pp collisions at sqrt[s]=1.96 TeV collected with the CDF II detector at the Fermilab Tevatron. We observe 16 WZ candidates passing our event selection with an expected background of 2.7+/-0.4 events. A fit to the missing transverse energy distribution indicates an excess of events compared to the background expectation corresponding to a significance equivalent to 6 standard deviations. The measured cross section is sigma(pp-->WZ)=5.0(-1.6)(+1.8) pb, consistent with the standard model expectation.